Damage Muscle, Performance Enhancing Product Use, Soreness, Muscle
Conditions
Brief summary
The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.
Interventions
DIETARY_SUPPLEMENTPre-workout plus and protein recovery plus
Study products consumed prior and after exercise
OTHERPlacebo
Placebo product consumed prior and after exercise
Sponsors
University of North Carolina, Chapel Hill
Pharmanex
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant is an adult between the ages of 25-50 years * Participant has a recorded BMI of 20-35 kg/m2 * Participant exercises less than 3 hours per week for at least 8 weeks preceding the study * Participant has provided written and dated informed consent to participate in the study * Participant is willing to and able to comply with the protocol * Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire * Participant agrees to maintain current diet and exercise routine during the study * Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise (acute) or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage * Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg
Exclusion criteria
* Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement * Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D * Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment * Participant has gained or lost ≥ 8 lbs in the previous month * Participant has a known allergy or sensitivity to the placebo or active ingredients * Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study * Participant is pregnant or planning to become pregnant * Participant has any musculoskeletal condition prohibiting them from participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance | baseline, 24 hours, 48 hours | Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle soreness | baseline, 24 hours, 48 hours | Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.) |
| Creatine Kinase | baseline, 24 hours, 48 hours | Change from baseline on muscle damage by measuring creatine kinase |
| Isoprostanes | baseline, 24 hours, 48 hours | Change from baseline on muscle damage by measuring isoprostanes |
Countries
United States
Outcome results
None listed